Global Gastric Mucosal Protective Agent Market Size By Type (Tablet, Chewable), By Application (Hospital, Laboratory), By Region, And Segment Forecasts, 2023 to 2032

The Global Gastric Mucosal Protective Agent Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.5 billion by 2031, growing at a CAGR of 6.2% during the forecast period (2023–2031). Gastric mucosal protective agents are used extensively in the treatment and prevention of gastric ulcers and other gastrointestinal (GI) tract disorders. The market is growing due to increasing cases of gastric irritation caused by NSAIDs (nonsteroidal anti-inflammatory drugs), rising stress-related GI conditions, and increasing awareness of gastrointestinal health.

Drivers:

1. Increasing Prevalence of GI Disorders:

The rising incidence of gastrointestinal disorders such as gastritis, peptic ulcers, and GERD is propelling the demand for protective agents that support mucosal healing and reduce acid exposure.

2. Growing Geriatric Population:

Older adults are more susceptible to GI disorders due to prolonged medication use and weakening mucosal barriers, fueling the market for mucosal protectants.

3. Expanding Use of NSAIDs and Aspirin:

With the widespread use of NSAIDs for pain and inflammation, there is a corresponding increase in drug-induced gastric complications, driving demand for protective agents.

Restraints:

1. Side Effects and Drug Interactions:

Some gastric mucosal protective agents may have side effects or interact negatively with other medications, limiting their usage.

2. Availability of Alternative Therapies:

The presence of alternative treatments such as proton pump inhibitors (PPIs) and H2-receptor antagonists can restrain the growth of this market.

Opportunity:

1. Development of Novel Agents with Enhanced Efficacy:

Ongoing R&D in gastroenterology is paving the way for the development of newer, more effective protective agents with fewer side effects.

2. Rising Awareness and Preventive Health Measures:

The global shift towards preventive healthcare and wellness is opening new avenues for over-the-counter mucosal protectants and dietary interventions.

Market by System Type Insights:

By system type, Cytoprotective agents held the largest market share in 2023. These agents, including sucralfate and misoprostol, are widely used for treating ulcers and preventing NSAID-related gastric damage. The prostaglandin analogs segment is expected to grow at a notable pace due to their superior protective function and increased adoption in high-risk patient populations.

Market by End-use Insights:

In terms of end-use, hospitals dominated the market in 2023, driven by high volumes of prescriptions for inpatient and emergency GI treatments. The retail pharmacies segment is anticipated to witness substantial growth owing to increasing self-medication trends and OTC availability of certain protective agents.

Market by Regional Insights:

Regionally, Asia-Pacific accounted for the largest market share in 2023, driven by a high prevalence of Helicobacter pylori infections and increased consumption of NSAIDs. North America is expected to grow significantly, supported by growing elderly populations and better healthcare access. Europe remains a strong market due to high healthcare spending and advanced gastroenterology practices.

Competitive Scenario:

Key players in the Global Gastric Mucosal Protective Agent Market include Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., Abbott Laboratories, Pfizer Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., and AstraZeneca plc. These companies are focusing on expanding product lines, investing in R&D, and forming strategic alliances to reinforce their market presence.

Key Market Developments:

2023: Eisai Co., Ltd. introduced a new formulation of its mucosal protectant with improved absorption and patient compliance.

2024: Daewoong Pharmaceutical expanded its global footprint by launching its flagship mucosal protective drug in Europe and Latin America.

2025: Pfizer Inc. announced a research collaboration aimed at developing next-generation gastroprotective agents targeting multiple pathways.

Scope of Work – Global Gastric Mucosal Protective Agent Market

FAQs:

1) What is the current market size of the Global Gastric Mucosal Protective Agent Market?

The market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Gastric Mucosal Protective Agent Market?

Rising prevalence of gastrointestinal disorders and increasing use of NSAIDs are the major growth drivers.

3) Which is the largest region during the forecast period in the Global Gastric Mucosal Protective Agent Market?

Asia-Pacific is the largest regional market and is expected to maintain dominance throughout the forecast period.

4) Which segment accounted for the largest market share in Global Gastric Mucosal Protective Agent Market?

The Cytoprotective Agents segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Gastric Mucosal Protective Agent Market?

Key players include Daewoong Pharmaceutical, Eisai, Abbott, Pfizer, Takeda, GlaxoSmithKline, Teva, and AstraZeneca.